MedTrace Logo

Breast Cancer Risk Assessment Using Optical Breast Spectroscopy (OBS)

NCT00500383 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 372

Last updated 2016-03-23

No results posted yet for this study

Summary

This study aims to evaluate if a light based technique, called Optical Breast Spectroscopy (OBS) formerly known as Transillumination Breast Spectroscopy (TiBS), can be used to detect differences in breast tissue between high- and low-risk populations and within the high-risk population between BrCa1 or 2 carriers and non-carriers. These differences may include differences in breast tissue composition and metabolism at time of enrollment into the study (possibly reflecting changes occurring in adolescence) and in the rate of breast tissue change over time (possibly reflecting rate of tissue transformation from normal to ultimately malignant state).

Conditions

Sponsors & Collaborators

  • Mount Sinai Hospital, Canada

    collaborator OTHER

  • Hamilton Health Sciences Corporation

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Lothar Lilge, PhD · Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada M5G 2M9; Department of Biophysics and Bioimaging, University of Toronto, Toronto, Ontario, Canada M5G 2M9

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2015-03-31
Completion
2015-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00500383 on ClinicalTrials.gov